Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Szarek

Showing results (1-10 of 152) with videos related to

Pageof 16
Sort By:
Biometrics|May 29, 2008
Nonparametric estimation in a Markov "illness-death" process from interval censored observations with missing intermediate transition statusHalina Frydman, Michael Szarek
Statistics in Medicine|August 5, 2010
Estimation of overall survival in an 'illness-death' model with application to the vertical transmission of HIV-1Halina Frydman, Michael Szarek
European Journal of Preventive Cardiology|October 8, 2024
Is it time to get SIRIUS about in silico modelling of cardiovascular outcomes trials?Marc P Bonaca, Michael Szarek, Gregory G Schwartz
Journal of Urban Health : Bulletin of the New York Academy of Medicine|October 5, 2013
The correlation between global health experiences in low-income countries on choice of primary care residencies for graduates of an urban US medical schoolDenise Marie Bruno, Pascal James Imperato, Michael Szarek
European Journal of Preventive Cardiology|March 10, 2025
Apolipoprotein C3, triglycerides, and cardiovascular risk in optimally treated ACS patients: The critical role of mediation analysis and implications for precision primary prevention: ReplyGregory G Schwartz, Michael Szarek, Philippe Gabriel Steg
The New England Journal of Medicine|May 23, 2019
Alirocumab after Acute Coronary Syndrome. ReplyGregory G Schwartz, P Gabriel Steg, Michael Szarek
The American Journal of Cardiology|September 16, 2003
Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patientsConnie B Newman, Gary Palmer, Halit Silbershatz, et al.
The American Journal of Cardiology|December 27, 2005
Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patientsConnie Newman, John Tsai, Michael Szarek, et al.
The Journal of Investigative Dermatology|August 25, 2005
Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanomaIrene J Vergilis, Michael Szarek, Soldano Ferrone, et al.
Diabetes Care|September 28, 2005
Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trialGregory G Schwartz, Anders G Olsson, Michael Szarek, et al.
Pageof 16

Showing results (1-10 of 152) with videos related to

Sort By:
Pageof 16
Biometrics|May 29, 2008
Nonparametric estimation in a Markov "illness-death" process from interval censored observations with missing intermediate transition statusHalina Frydman, Michael Szarek
Statistics in Medicine|August 5, 2010
Estimation of overall survival in an 'illness-death' model with application to the vertical transmission of HIV-1Halina Frydman, Michael Szarek
European Journal of Preventive Cardiology|October 8, 2024
Is it time to get SIRIUS about in silico modelling of cardiovascular outcomes trials?Marc P Bonaca, Michael Szarek, Gregory G Schwartz
Journal of Urban Health : Bulletin of the New York Academy of Medicine|October 5, 2013
The correlation between global health experiences in low-income countries on choice of primary care residencies for graduates of an urban US medical schoolDenise Marie Bruno, Pascal James Imperato, Michael Szarek
European Journal of Preventive Cardiology|March 10, 2025
Apolipoprotein C3, triglycerides, and cardiovascular risk in optimally treated ACS patients: The critical role of mediation analysis and implications for precision primary prevention: ReplyGregory G Schwartz, Michael Szarek, Philippe Gabriel Steg
The New England Journal of Medicine|May 23, 2019
Alirocumab after Acute Coronary Syndrome. ReplyGregory G Schwartz, P Gabriel Steg, Michael Szarek
The American Journal of Cardiology|September 16, 2003
Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patientsConnie B Newman, Gary Palmer, Halit Silbershatz, et al.
The American Journal of Cardiology|December 27, 2005
Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patientsConnie Newman, John Tsai, Michael Szarek, et al.
The Journal of Investigative Dermatology|August 25, 2005
Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanomaIrene J Vergilis, Michael Szarek, Soldano Ferrone, et al.
Diabetes Care|September 28, 2005
Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trialGregory G Schwartz, Anders G Olsson, Michael Szarek, et al.
Pageof 16